BACKGROUND: Children <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown. METHODS: The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group evaluated oseltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic exposure. RESULTS: From 2006 to 2010, 87 subjects enrolled. An oseltamivir dose of 3.0 mg/kg produced drug exposures within the target range in subjects 0-8 months of age, although there was a greater degree of variability in infants <3 months of age. In subjects 9-11 months of age, a dose of 3.5 mg/kg produced drug exposures within the target range. Six of 10 subjects aged 12-23 months receiving the Food and Drug Administration-approved unit dose for this age group (ie, 30 mg) had oseltamivir carboxylate exposures below the target range. Virus from 3 subjects developed oseltamivir resistance during antiviral treatment. CONCLUSIONS: The appropriate twice-daily oral oseltamivir dose for infants ≤8 months of age is 3.0 mg/kg, while the dose for infants 9-11 months old is 3.5 mg/kg.
BACKGROUND:Children <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown. METHODS: The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group evaluated oseltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic exposure. RESULTS: From 2006 to 2010, 87 subjects enrolled. An oseltamivir dose of 3.0 mg/kg produced drug exposures within the target range in subjects 0-8 months of age, although there was a greater degree of variability in infants <3 months of age. In subjects 9-11 months of age, a dose of 3.5 mg/kg produced drug exposures within the target range. Six of 10 subjects aged 12-23 months receiving the Food and Drug Administration-approved unit dose for this age group (ie, 30 mg) had oseltamivir carboxylate exposures below the target range. Virus from 3 subjects developed oseltamivir resistance during antiviral treatment. CONCLUSIONS: The appropriate twice-daily oral oseltamivir dose for infants ≤8 months of age is 3.0 mg/kg, while the dose for infants 9-11 months old is 3.5 mg/kg.
Authors: Michael G Ison; Menno D de Jong; Kevin J Gilligan; Elizabeth S Higgs; Andrew T Pavia; Jerome Pierson; Frederick G Hayden Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: H Harvala; R Gunson; P Simmonds; A Hardie; S Bennett; F Scott; H Roddie; J McKnight; T Walsh; D Rowney; A Clark; J Bremner; C Aitken; K Templeton Journal: Euro Surveill Date: 2010-04-08
Authors: Edward P Acosta; Penelope Jester; Peter Gal; John Wimmer; Joni Wade; Richard J Whitley; David W Kimberlin Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Bin Wang; Dominic E Dwyer; Christopher C Blyth; Maly Soedjono; Haijing Shi; Alison Kesson; Mala Ratnamohan; Ken McPhie; Anthony L Cunningham; Nitin K Saksena Journal: Antiviral Res Date: 2010-04-10 Impact factor: 5.970
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Kelvin K W To; Ivan F N Hung; Iris W S Li; Kar-Lung Lee; Chi-Kwan Koo; Wing-Wa Yan; Raymond Liu; Ka-Ying Ho; Kwok-Hong Chu; Chi-Leung Watt; Wei-Kwang Luk; Kang-Yiu Lai; Fu-Loi Chow; Thomas Mok; Tom Buckley; Jasper F W Chan; Samson S Y Wong; Bojian Zheng; Honglin Chen; Candy C Y Lau; Herman Tse; Vincent C C Cheng; Kwok-Hung Chan; Kwok-Yung Yuen Journal: Clin Infect Dis Date: 2010-03-15 Impact factor: 9.079
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing Journal: Adv Drug Deliv Rev Date: 2014-01-17 Impact factor: 15.470
Authors: H Grant Stiver; Gerald A Evans; Fred Y Aoki; Upton D Allen; Michel Laverdière Journal: Can J Infect Dis Med Microbiol Date: 2015 Jan-Feb Impact factor: 2.471
Authors: Sudhir Venkatesan; Puja R Myles; Kirsty J Bolton; Stella G Muthuri; Tarig Al Khuwaitir; Ashish P Anovadiya; Eduardo Azziz-Baumgartner; Tahar Bajjou; Matteo Bassetti; Bojana Beovic; Barbara Bertisch; Isabelle Bonmarin; Robert Booy; Victor H Borja-Aburto; Heinz Burgmann; Bin Cao; Jordi Carratala; Tserendorj Chinbayar; Catia Cilloniz; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Sergio Fanella; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath Lorena Higuera Iglesias; Peter H Hoeger; Xiao Yun Hu; Quazi T Islam; Mirela F Jiménez; Gerben Keijzers; Hossein Khalili; Gabriela Kusznierz; Ilija Kuzman; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Romina P Libster; Rita Linko; Faris Madanat; Efstratios Maltezos; Abdullah Mamun; Toshie Manabe; Gokhan Metan; Auksė Mickiene; Dragan Mikić; Kristin G I Mohn; Maria E Oliva; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Barbara A Rath; Samir Refaey; Alejandro H Rodríguez; Bunyamin Sertogullarindan; Joanna Skręt-Magierło; Ayper Somer; Ewa Talarek; Julian W Tang; Kelvin To; Dat Tran; Timothy M Uyeki; Wendy Vaudry; Tjasa Vidmar; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam Journal: J Infect Dis Date: 2020-01-14 Impact factor: 5.226
Authors: Stella G Muthuri; Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Tarig S A Al Khuwaitir; Adbullah Al Mamun; Ashish P Anovadiya; Eduardo Azziz-Baumgartner; Clarisa Báez; Matteo Bassetti; Bojana Beovic; Barbara Bertisch; Isabelle Bonmarin; Robert Booy; Victor H Borja-Aburto; Heinz Burgmann; Bin Cao; Jordi Carratala; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Marcela Echavarria; Sergio Fanella; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath L Higuera Iglesias; Peter H Hoger; Xiaoyun Hu; Quazi T Islam; Mirela F Jiménez; Amr Kandeel; Gerben Keijzers; Hossein Khalili; Marian Knight; Koichiro Kudo; Gabriela Kusznierz; Ilija Kuzman; Arthur M C Kwan; Idriss Lahlou Amine; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Rita Linko; Pei Liu; Faris Madanat; Elga Mayo-Montero; Allison McGeer; Ziad Memish; Gokhan Metan; Auksė Mickiene; Dragan Mikić; Kristin G I Mohn; Ahmadreza Moradi; Pagbajabyn Nymadawa; Maria E Oliva; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Fernando P Polack; Barbara A Rath; Alejandro H Rodríguez; Elena B Sarrouf; Anna C Seale; Bunyamin Sertogullarindan; Marilda M Siqueira; Joanna Skręt-Magierło; Frank Stephan; Ewa Talarek; Julian W Tang; Kelvin K W To; Antoni Torres; Selda H Törün; Dat Tran; Timothy M Uyeki; Annelies Van Zwol; Wendy Vaudry; Tjasa Vidmar; Renata T C Yokota; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam Journal: Lancet Respir Med Date: 2014-03-19 Impact factor: 30.700
Authors: Natalia Sutiman; Janine Cynthia Koh; Kevin Watt; Christoph Hornik; Beverly Murphy; Yoke Hwee Chan; Jan Hau Lee Journal: Front Pediatr Date: 2020-06-26 Impact factor: 3.418